Kidney disease in patients with two APOL1 risk variants

Area of Science:

• Genetics
• Nephrology
• Precision Medicine

Background:

• Kidney disease diagnoses were historically based on factors like high blood sugar and pressure.
• Significant disparities in kidney failure rates among different ethnic groups, especially African Americans, were poorly understood.
• The concept of precision medicine has revolutionized diagnostic approaches in nephrology.

Purpose of the Study:

• To review the discovery of the apolipoprotein L1 (APOL1) gene and its association with chronic kidney disease (CKD).
• To explain how APOL1 variants contribute to kidney failure incidence and outcomes in specific populations.
• To discuss the implications of APOL1 on understanding kidney disease susceptibility and guiding future research.

Main Methods:

• Review of scientific literature focusing on the APOL1 gene discovery.
• Analysis of genetic testing data in nephrology patients.
• Examination of epidemiological data on kidney failure rates and ethnic disparities.

Main Results:

• The discovery of APOL1 variants in 2010 revealed their strong association with CKD.
• APOL1 gene variants account for over 35% of kidney failure cases in individuals of African ancestry.
• APOL1 influences disparities in nephropathy incidence, kidney transplantation, and live kidney donation outcomes.

Conclusions:

• The APOL1 gene discovery has fundamentally changed the understanding of kidney disease, particularly in African Americans.
• APOL1-associated kidney injury mechanisms and potential novel therapies are areas of ongoing research.
• Further investigation is needed to address knowledge gaps and explore future therapeutic strategies for APOL1-related nephropathies.